TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Teladoc Health Inc (TDOC) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock's financial performance is weak, with declining net income, EPS, and gross margin. Analysts have been lowering price targets, and there is no recent positive momentum in trading trends or proprietary trading signals. While there is some optimism in parts of the business, the company is in a competitive market and undergoing a transition, which adds uncertainty.
The MACD is above 0 and positively contracting, suggesting mild bullish momentum. RSI is neutral at 57.02, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 5.462, with resistance at 5.63 and support at 5.294.
Deutsche Bank upgraded the stock to Buy with an $11 price target, citing a compelling valuation and a deliverable strategy for its BetterHelp business. BofA also raised its price target, highlighting undervaluation in Teladoc's virtual therapy business.
Barclays, JPMorgan, and several other analysts have lowered price targets, reflecting concerns over the company's competitive positioning and transition challenges. Financial performance in Q4 2025 showed declining net income and EPS, with gross margin also dropping.
In Q4 2025, revenue increased slightly by 0.28% YoY to $642.27M. However, net income dropped significantly by 48.06% YoY to -$25.14M, and EPS fell by 50% YoY to -$0.14. Gross margin also declined by 3.5% YoY to 54.55%.
Mixed ratings with a recent trend of price target reductions. Barclays lowered its target to $7, JPMorgan to $7, and Citi to $6, all maintaining Neutral ratings. However, Deutsche Bank upgraded the stock to Buy with an $11 target, and BofA raised its target to $8.25, citing undervaluation and potential growth in the virtual therapy business.
